David Ormesher

CEO | CG Life

February 2026
In this DHCG Disruptive Dose, Mark Bard speaks with David Ormesher, CEO at CG Life, about moving AI from pilots to operational reality in healthcare marketing. Ormesher emphasizes that successful implementation requires clear use cases tied to business outcomes, robust governance frameworks, and organizational change management beyond just technology. He discusses why pharma AI initiatives stall, the importance of measuring ROI through efficiency and quality improvements while managing compliance, and establishing governance that balances innovation with risk. Ormesher offers practical guidance on starting with high-impact, low-risk use cases to build confidence, investing in training alongside technology, and maintaining focus on solving real business problems rather than chasing AI capabilities for their own sake.